PNPO Deficiency

🔗

Mappings

MONDO

MONDO:0012407 pyridoxal phosphate-responsive seizures

MONDO:0012407 is the PNPO deficiency (pyridoxal phosphate-responsive seizures) concept.

👪

Inheritance

1

Autosomal recessive inheritance HP:0000007

PNPO deficiency is inherited in an autosomal recessive manner; affected individuals carry biallelic pathogenic PNPO variants. At conception, each sib of an affected proband has a 25% chance of being affected.

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:35737815 SUPPORT Human Clinical

"a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."

GeneReviews documents the autosomal recessive 25% sibling recurrence risk.

?

Discussions and Knowledge Gaps

3

What determines whether an individual with PNPO deficiency responds to pyridoxal 5'-phosphate versus pyridoxine, does genotype predict it, and how should the diagnostic caveat that CSF PLP can be normal be handled to avoid missed diagnoses?

KNOWLEDGE GAP OPEN gap_pnpo_plp_vs_pyridoxine_responsiveness_and_diagnostic_caveat

Attached to

pathophysiology#B6-Vitamer-Responsive Neonatal Seizures pathophysiology#Pyridoxal 5-Phosphate Deficiency

Most individuals respond to PLP and a minority to pyridoxine, but the determinants (specific variant, residual enzyme activity) are incompletely defined, and choosing the wrong vitamer or dose has real consequences (PLP carries a risk of liver toxicity, high-dose pyridoxine of neuropathy). Compounding this, CSF PLP - an expected biomarker - can be normal in a genetically confirmed patient, so a normal level does not exclude the diagnosis. Resolving the genotype-to-vitamer map and the reliable diagnostic pathway is directly actionable for this treatable disorder.

Proposed experiments

Genotype-to-vitamer-response mapping in PNPO deficiency

genotype-response correlation experiment

exp_pnpo_genotype_vitamer_response

Correlate PNPO variant class and residual enzyme activity (in vitro and in patient cells) with clinical response to PLP versus pyridoxine, to test whether functional genotype predicts the effective vitamer.

Readouts

Vitamer response by genotype

pathophysiology#B6-Vitamer-Responsive Neonatal Seizures

enzyme activity assay

Direction: POSITIVE

Controls

Wild-type PNPO

Wild-type enzyme as the activity reference.

Decision criterion

Genotype predicts vitamer response if residual-activity class reliably separates PLP-responsive from pyridoxine-responsive individuals.

Would support

pathophysiology#B6-Vitamer-Responsive Neonatal Seizures

Show evidence (1 reference)

PMID:25762494 SUPPORT Human Clinical

"a normal CSF level of pyridoxal 5'-phosphate does not rule out PNPO deficiency."

Documents that a normal CSF PLP does not exclude PNPO deficiency, the diagnostic caveat this gap concerns.

Are the prematurity and fetal distress so commonly seen at presentation of PNPO deficiency true predisposing factors, or early manifestations of the disease itself (for example in-utero seizures and distress)?

KNOWLEDGE GAP OPEN gap_pnpo_prematurity_risk_versus_manifestation

Attached to

pathophysiology#B6-Vitamer-Responsive Neonatal Seizures

Premature birth and fetal distress recur as associated features across PNPO cohorts. If they are prodromal manifestations of prenatal disease, they could serve as early warning signs prompting a B6 trial; if they are genuine modifiers, they might worsen outcome independently. Distinguishing the two affects both early recognition and prognostic counseling.

Proposed experiments

Perinatal-feature causal analysis in PNPO deficiency

perinatal association analysis experiment

exp_pnpo_perinatal_association

In a prospective PNPO cohort, relate prenatal/perinatal findings and timing of metabolite/PLP disturbance to gestational age and outcome, to test whether prematurity precedes or follows the earliest disease markers.

Readouts

Timing of perinatal features versus disease markers

pathophysiology#B6-Vitamer-Responsive Neonatal Seizures

clinical assessment

Direction: POSITIVE

Controls

Gestational-age-matched comparison

Comparison against gestational-age-matched populations.

Decision criterion

Prematurity is an early manifestation if it co-occurs with or follows the earliest disease markers rather than independently preceding them.

Would support

pathophysiology#B6-Vitamer-Responsive Neonatal Seizures

Show evidence (1 reference)

PMID:32888189 SUPPORT Human Clinical

"Pre-maturity and fetal distress, combined with neonatal seizures, are other associated key characteristics."

Documents the recurrent prematurity/fetal-distress association whose causal status is the open question.

PNPO deficiency and ALDH7A1 pyridoxine-dependent epilepsy both converge on intracellular pyridoxal 5'-phosphate deficiency yet differ in vitamer responsiveness and treatment safety - why does developmental impairment persist despite vitamer treatment, and does the shared final pathway imply shared adjunct strategies?

KNOWLEDGE GAP OPEN gap_pnpo_shared_plp_pathway_with_pde_and_residual_impairment

Attached to

pathophysiology#Neurodevelopmental Impairment pathophysiology#Pyridoxal 5-Phosphate Deficiency

Both PNPO deficiency and ALDH7A1 pyridoxine-dependent epilepsy produce a functional PLP deficiency and a treatable neonatal epilepsy, but PNPO usually needs PLP (with hepatotoxicity risk) while ALDH7A1 needs pyridoxine (plus metabolite-lowering diet). In both, seizures respond yet a substantial share of patients have lasting developmental impairment. Whether the residual impairment reflects the shared PLP-cofactor failure (broad neurotransmitter and metabolic disruption) during a critical window, and whether adjuncts proven in one disorder transfer to the other, is an open, clinically relevant question. This entry deliberately mirrors the Pyridoxine-Dependent Epilepsy entry's dissociation gap.

Proposed experiments

Shared PLP-deficiency mechanisms across PNPO and ALDH7A1 disease

cross-disorder shared-pathway experiment

exp_pnpo_pde_shared_pathway

Compare neuronal PLP-dependent enzyme activity, neurotransmitter profiles, and developmental readouts across PNPO-deficient and ALDH7A1-deficient human neuronal models under vitamer treatment, to identify shared residual deficits and transferable adjunct targets.

Readouts

Residual PLP-dependent deficits under treatment

pathophysiology#Neurodevelopmental Impairment

enzyme activity assay metabolite profiling assay

Direction: POSITIVE

Controls

Vitamer-treated wild-type

Wild-type neurons under matched vitamer treatment.

Decision criterion

A shared residual mechanism is supported if both disorders retain the same PLP-dependent deficits under vitamer treatment, nominating a common adjunct target.

Would support

pathophysiology#Neurodevelopmental Impairment

Show evidence (1 reference)

PMID:15772097 SUPPORT Human Clinical

"reduced activity of aromatic L-amino acid decarboxylase and other PLP-dependent enzymes."

Establishes the broad PLP-cofactor failure shared with other PLP-deficiency epilepsies, the basis for asking about residual impairment and shared adjuncts.

⚙

Pathophysiology

7

PNPO Deficiency

Biallelic loss-of-function variants in PNPO reduce or abolish pyridox(am)ine 5'-phosphate oxidase activity. This node captures the single concept of the enzyme deficiency.

PNPO hgnc:30260

Pyridoxamine phosphate oxidase activity GO:0004733 ↓ DECREASED

Downstream

Impaired Synthesis of Pyridoxal 5-Phosphate Loss of PNPO blocks oxidation of pyridoxine/pyridoxamine phosphate to PLP.

Show evidence (1 reference)

PMID:15772097 SUPPORT Human Clinical

"reduced activity of aromatic L-amino acid decarboxylase and other PLP-dependent enzymes."

The founding study linked PNPO mutations to a global failure of PLP-dependent enzymes, the biochemical basis of the disorder.

Impaired Synthesis of Pyridoxal 5-Phosphate

PNPO catalyzes the final step of PLP synthesis from dietary pyridoxine and pyridoxamine phosphates; its loss prevents formation of the active vitamin B6 cofactor by this route. This node captures the single concept of the blocked PLP synthesis.

Downstream

Pyridoxal 5-Phosphate Deficiency The synthetic block lowers the intracellular pool of active PLP.

Pyridoxal 5-Phosphate Deficiency

Insufficient PLP, the active vitamin B6 cofactor, results. This node captures the single concept of the cofactor deficiency, which pharmacologic PLP (or, in some individuals, pyridoxine) can overcome.

Downstream

Impaired PLP-Dependent GABA Synthesis and Excitation-Inhibition Imbalance PLP deficiency impairs the many PLP-dependent neuronal enzymes, notably glutamic acid decarboxylase.

Impaired PLP-Dependent GABA Synthesis and Excitation-Inhibition Imbalance

Glutamic acid decarboxylase requires PLP to synthesize the inhibitory neurotransmitter GABA; PLP deficiency lowers GABA synthesis and shifts cortical circuits toward excitation. This node captures the single concept of the excitation-inhibition imbalance and conforms to the shared epilepsy final common pathway.

GABAergic interneuron CL:0000617

Downstream

Neuronal Hyperexcitability Reduced inhibitory tone renders neonatal networks hyperexcitable.

Neuronal Hyperexcitability

Networks with reduced GABAergic inhibition become hyperexcitable and hypersynchronous. This node captures the single concept of network hyperexcitability and conforms to the shared epilepsy final common pathway.

Neuron CL:0000540

Downstream

B6-Vitamer-Responsive Neonatal Seizures Hyperexcitable networks generate the neonatal-onset seizures.

B6-Vitamer-Responsive Neonatal Seizures

The clinical hallmark is neonatal-onset seizures (including status epilepticus and multiple semiologies) resistant to standard antiseizure medication but responsive to a B6 vitamer - pyridoxal 5'-phosphate in most individuals and pyridoxine in a minority. This node captures the single concept of the treatable seizure endpoint and conforms to the shared epilepsy final common pathway.

Neuron CL:0000540

Show evidence (1 reference)

PMID:35737815 SUPPORT Human Clinical

"Independent of age of onset, seizures respond to life-long treatment with a B6 vitamer: pyridoxal 5'-phosphate (PLP) in about 60% of affected individuals and pyridoxine (PN) in about 40%."

GeneReviews documents the defining B6-vitamer responsiveness (PLP in most, pyridoxine in a minority).

Neurodevelopmental Impairment

Developmental impairment affecting speech, cognition, and behavior is common (about 60%), and is more likely with diagnostic delay and prolonged uncontrolled seizures. This node captures the single concept of the neurodevelopmental outcome.

Neuron CL:0000540

Show evidence (1 reference)

PMID:35737815 SUPPORT Human Clinical

"About 60% of individuals with PNPO deficiency have developmental impairment, affecting speech, cognition, and behavior"

GeneReviews documents the frequent developmental impairment.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

7

Musculoskeletal 1

Hypotonia HP:0001252

Nervous System 3

Tonic Seizures HP:0032792

Developmental Impairment Global developmental delay HP:0001263

Dystonia HP:0001332

Other 3

Neonatal-Onset Seizures Neonatal seizure HP:0032807

Show evidence (1 reference)

PMID:35737815 SUPPORT Human Clinical

"In classic PNPO deficiency, seizures (including status epilepticus) often begin on the first day of life and typically before age two weeks."

GeneReviews documents neonatal seizure onset in classic PNPO deficiency.

Status Epilepticus HP:0002133

Myoclonic Seizures HP:0032794

🧬

Genetic Associations

1

PNPO

Gene: PNPO hgnc:30260 relationship_type: CAUSATIVE

💊

Medical Actions

3

Pyridoxal 5-Phosphate Supplementation

Action: Pharmacotherapy NCIT:C15986

Agent: pyridoxal 5'-phosphate CHEBI:18405

Lifelong pyridoxal 5'-phosphate (PLP, the active vitamin B6 cofactor) is the targeted therapy that controls seizures in most individuals; the lowest effective dose is used because of possible liver toxicity.

Show evidence (1 reference)

PMID:35737815 SUPPORT Human Clinical

"Independent of age of onset, seizures respond to life-long treatment with a B6 vitamer: pyridoxal 5'-phosphate (PLP) in about 60% of affected individuals and pyridoxine (PN) in about 40%."

GeneReviews documents PLP as the targeted therapy effective in most individuals.

Pyridoxine Supplementation

Action: Pharmacotherapy NCIT:C15986

Agent: pyridoxine CHEBI:16709

A minority of individuals respond to pyridoxine (PN) rather than PLP; pyridoxine can cause reversible sensory (or motor) neuropathy at high doses.

Antiseizure Medications to Avoid

Action: Pharmacotherapy NCIT:C15986

PLP-lowering antiseizure medications (carbamazepine, valproate, phenytoin, phenobarbital) should be avoided because they can further reduce plasma PLP.

Show evidence (1 reference)

PMID:35737815 SUPPORT Human Clinical

"Avoid anti-seizure medications (such as carbamazepine, valproate, phenytoin, and phenobarbital) that can reduce plasma PLP concentration."

GeneReviews lists PLP-lowering antiseizure medications among agents to avoid.

🔬

Biochemical Markers

3

Elevated Urinary Vanillactic Acid (INCREASED)

Show evidence (1 reference)

PMID:32888189 SUPPORT Human Clinical

"cerebrospinal fluid (CSF) PLP was low in 81%, CSF glycine was high in 80% and urinary vanillactic acid was high in 91% of the cases."

The scoping review quantifies the diagnostic biomarkers: urinary vanillactic acid high in 91%, CSF glycine high in 80%, CSF PLP low in 81%.

Low CSF Pyridoxal 5-Phosphate (DECREASED)

Show evidence (1 reference)

PMID:32888189 SUPPORT Human Clinical

"cerebrospinal fluid (CSF) PLP was low in 81%, CSF glycine was high in 80% and urinary vanillactic acid was high in 91% of the cases."

CSF PLP was low in 81% of cases.

Elevated CSF Glycine (INCREASED)

Show evidence (1 reference)

PMID:32888189 SUPPORT Human Clinical

"cerebrospinal fluid (CSF) PLP was low in 81%, CSF glycine was high in 80% and urinary vanillactic acid was high in 91% of the cases."

CSF glycine was high in 80% of cases.

🔬

Diagnosis

1

PNPO Molecular Genetic Testing and B6 Trial

Diagnosis is established by a positive standardized vitamin B6 trial in an infant with treatment-resistant seizures together with biallelic pathogenic PNPO variants (or deficient PNPO enzyme activity).

Show evidence (1 reference)

PMID:35737815 SUPPORT Human Clinical

"The diagnosis of PNPO deficiency is established in a proband with suggestive findings"

GeneReviews establishes the combined B6-trial-plus-molecular diagnostic pathway.

📊

Prevalence

1

Worldwide

Cases In Literature Rare

A rare autosomal recessive inborn error of vitamin B6 metabolism; no precise population rate is established. A scoping review assembled 87 reported cases, indicating the disorder's rarity while noting likely underdiagnosis given the treatable, potentially fatal-if-missed presentation.

Show evidence (1 reference)

PMID:32888189 SUPPORT Human Clinical

"A scoping review of 87 cases of pyridoxamine-5'-phosphate oxidase deficiency"

Provides a literature case count reflecting the rarity of the disorder; no normalized population rate is asserted.

{ }

Source YAML

click to show

name: PNPO Deficiency
creation_date: "2026-07-18T00:00:00Z"
category: Mendelian
description: >-
  PNPO deficiency (pyridox(am)ine 5'-phosphate oxidase deficiency) is an
  autosomal recessive, treatable metabolic epilepsy. PNPO is the enzyme that
  oxidizes pyridoxine 5'-phosphate and pyridoxamine 5'-phosphate to pyridoxal
  5'-phosphate (PLP), the active cofactor form of vitamin B6. Its deficiency
  causes PLP insufficiency and, because PLP is the cofactor for glutamic acid
  decarboxylase and many neuronal enzymes, impairs GABA synthesis and produces
  neonatal-onset seizures that resist standard antiseizure medication but respond
  to a B6 vitamer - PLP in most individuals and pyridoxine in a minority. Onset
  is usually in the neonatal period (classic form). Developmental impairment is
  common, particularly with diagnostic delay. The disorder is the
  PLP-synthesis-failure counterpart of ALDH7A1 pyridoxine-dependent epilepsy,
  with both converging on intracellular PLP deficiency.
parents:
- Epilepsy
- Inborn Errors of Metabolism
- Neurodevelopmental Disorder
synonyms:
- Pyridox(am)ine 5'-phosphate oxidase deficiency
- Pyridoxal phosphate-responsive seizures
- PNPO-related neonatal epileptic encephalopathy
- Pyridoxal 5'-phosphate-dependent epilepsy
disease_term:
  preferred_term: PNPO deficiency
  term:
    id: MONDO:0012407
    label: pyridoxal phosphate-responsive seizures
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0012407
      label: pyridoxal phosphate-responsive seizures
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0012407 is the PNPO deficiency (pyridoxal phosphate-responsive
      seizures) concept.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    PNPO deficiency is inherited in an autosomal recessive manner; affected
    individuals carry biallelic pathogenic PNPO variants. At conception, each sib
    of an affected proband has a 25% chance of being affected.
  evidence:
  - reference: PMID:35737815
    reference_title: "PNPO Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."
    explanation: GeneReviews documents the autosomal recessive 25% sibling recurrence risk.
pathophysiology:
- name: PNPO Deficiency
  description: >-
    Biallelic loss-of-function variants in PNPO reduce or abolish
    pyridox(am)ine 5'-phosphate oxidase activity. This node captures the single
    concept of the enzyme deficiency.
  role: trigger
  gene:
    preferred_term: PNPO
    term:
      id: hgnc:30260
      label: PNPO
  molecular_functions:
  - preferred_term: Pyridoxamine phosphate oxidase activity
    term:
      id: GO:0004733
      label: pyridoxamine phosphate oxidase activity
    modifier: DECREASED
  evidence:
  - reference: PMID:15772097
    reference_title: "Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "reduced activity of aromatic L-amino acid decarboxylase and other PLP-dependent enzymes."
    explanation: >-
      The founding study linked PNPO mutations to a global failure of
      PLP-dependent enzymes, the biochemical basis of the disorder.
  downstream:
  - target: Impaired Synthesis of Pyridoxal 5-Phosphate
    causal_link_type: DIRECT
    description: >-
      Loss of PNPO blocks oxidation of pyridoxine/pyridoxamine phosphate to PLP.
    evidence:
    - reference: PMID:33421502
      reference_title: "Inborn errors in the vitamin B6 salvage enzymes associated with neonatal epileptic encephalopathy and other pathologies."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Three key enzymes, pyridoxal kinase (PL kinase), pyridoxine 5'-phosphate oxidase (PNPO), and phosphatases metabolize and supply PLP to PLP-dependent enzymes through the salvage pathway."
      explanation: >-
        Places PNPO in the salvage pathway that supplies PLP, so loss of the
        enzyme is loss of that supply route. Evidence source is OTHER because
        this is a review article.
- name: Impaired Synthesis of Pyridoxal 5-Phosphate
  description: >-
    PNPO catalyzes the final step of PLP synthesis from dietary pyridoxine and
    pyridoxamine phosphates; its loss prevents formation of the active vitamin B6
    cofactor by this route. This node captures the single concept of the blocked
    PLP synthesis.
  role: mediator
  downstream:
  - target: Pyridoxal 5-Phosphate Deficiency
    causal_link_type: DIRECT
    description: >-
      The synthetic block lowers the intracellular pool of active PLP.
    evidence:
    - reference: PMID:33421502
      reference_title: "Inborn errors in the vitamin B6 salvage enzymes associated with neonatal epileptic encephalopathy and other pathologies."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "In born errors in the salvage enzymes are known to cause inadequate levels of PLP in the cell, particularly in neuronal cells."
      explanation: >-
        States that inborn errors of the salvage enzymes - PNPO among them -
        produce inadequate intracellular PLP, and specifically in neurons.
        Evidence source is OTHER because this is a review article.
- name: Pyridoxal 5-Phosphate Deficiency
  description: >-
    Insufficient PLP, the active vitamin B6 cofactor, results. This node
    captures the single concept of the cofactor deficiency, which pharmacologic
    PLP (or, in some individuals, pyridoxine) can overcome.
  role: mediator
  downstream:
  - target: Impaired PLP-Dependent GABA Synthesis and Excitation-Inhibition Imbalance
    causal_link_type: DIRECT
    description: >-
      PLP deficiency impairs the many PLP-dependent neuronal enzymes, notably
      glutamic acid decarboxylase.
    evidence:
    - reference: PMID:33421502
      reference_title: "Inborn errors in the vitamin B6 salvage enzymes associated with neonatal epileptic encephalopathy and other pathologies."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The PLP-dependent enzyme, L-glutamic acid decarboxylase (GAD) catalyzes the synthesis of GABA from L-glutamate"
      explanation: >-
        Establishes the PLP dependency of glutamic acid decarboxylase, the step
        through which a PLP shortage lowers GABA synthesis. Evidence source is
        OTHER because this is a review article.
- name: Impaired PLP-Dependent GABA Synthesis and Excitation-Inhibition Imbalance
  description: >-
    Glutamic acid decarboxylase requires PLP to synthesize the inhibitory
    neurotransmitter GABA; PLP deficiency lowers GABA synthesis and shifts
    cortical circuits toward excitation. This node captures the single concept of
    the excitation-inhibition imbalance and conforms to the shared epilepsy final
    common pathway.
  role: mediator
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
  cell_types:
  - preferred_term: GABAergic interneuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  downstream:
  - target: Neuronal Hyperexcitability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Reduced inhibitory tone renders neonatal networks hyperexcitable.
    evidence:
    - reference: PMID:30764523
      reference_title: "Pediatric Epilepsy Mechanisms: Expanding the Paradigm of Excitation/Inhibition Imbalance."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "increased excitation, decreased inhibition, or both favor a hyperexcitable state"
      explanation: >-
        States the general mechanism this edge specializes: loss of inhibitory
        tone produces a hyperexcitable network state. Evidence source is OTHER
        because this is a review article, and the link is annotated
        INDIRECT_KNOWN_INTERMEDIATES accordingly.
- name: Neuronal Hyperexcitability
  description: >-
    Networks with reduced GABAergic inhibition become hyperexcitable and
    hypersynchronous. This node captures the single concept of network
    hyperexcitability and conforms to the shared epilepsy final common pathway.
  role: central_effector
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: B6-Vitamer-Responsive Neonatal Seizures
    causal_link_type: DIRECT
    description: >-
      Hyperexcitable networks generate the neonatal-onset seizures.
    evidence:
    - reference: PMID:30764523
      reference_title: "Pediatric Epilepsy Mechanisms: Expanding the Paradigm of Excitation/Inhibition Imbalance."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "a hyperexcitable state and an increased propensity for seizure generation and epileptogenesis"
      explanation: >-
        Connects the hyperexcitable network state to seizure generation, the
        step this edge asserts. Evidence source is OTHER because this is a
        review article.
- name: B6-Vitamer-Responsive Neonatal Seizures
  description: >-
    The clinical hallmark is neonatal-onset seizures (including status
    epilepticus and multiple semiologies) resistant to standard antiseizure
    medication but responsive to a B6 vitamer - pyridoxal 5'-phosphate in most
    individuals and pyridoxine in a minority. This node captures the single
    concept of the treatable seizure endpoint and conforms to the shared
    epilepsy final common pathway.
  role: consequence
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:35737815
    reference_title: "PNPO Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Independent of age of onset, seizures respond to life-long treatment with a B6 vitamer: pyridoxal 5'-phosphate (PLP) in about 60% of affected individuals and pyridoxine (PN) in about 40%."
    explanation: >-
      GeneReviews documents the defining B6-vitamer responsiveness (PLP in most,
      pyridoxine in a minority).
- name: Neurodevelopmental Impairment
  description: >-
    Developmental impairment affecting speech, cognition, and behavior is common
    (about 60%), and is more likely with diagnostic delay and prolonged
    uncontrolled seizures. This node captures the single concept of the
    neurodevelopmental outcome.
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:35737815
    reference_title: "PNPO Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About 60% of individuals with PNPO deficiency have developmental impairment, affecting speech, cognition, and behavior"
    explanation: >-
      GeneReviews documents the frequent developmental impairment.
phenotypes:
- name: Neonatal-Onset Seizures
  description: >-
    Seizures often begin on the first day of life and typically before age two
    weeks in classic PNPO deficiency.
  phenotype_term:
    preferred_term: Neonatal seizure
    term:
      id: HP:0032807
      label: Neonatal seizure
  evidence:
  - reference: PMID:35737815
    reference_title: "PNPO Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In classic PNPO deficiency, seizures (including status epilepticus) often begin on the first day of life and typically before age two weeks."
    explanation: GeneReviews documents neonatal seizure onset in classic PNPO deficiency.
- name: Status Epilepticus
  description: Status epilepticus is common in untreated classic PNPO deficiency.
  phenotype_term:
    preferred_term: Status epilepticus
    term:
      id: HP:0002133
      label: Status epilepticus
- name: Myoclonic Seizures
  description: Myoclonic seizures are among the seizure semiologies.
  phenotype_term:
    preferred_term: Myoclonic seizure
    term:
      id: HP:0032794
      label: Myoclonic seizure
- name: Tonic Seizures
  description: Tonic seizures are among the seizure semiologies.
  phenotype_term:
    preferred_term: Tonic seizure
    term:
      id: HP:0032792
      label: Tonic seizure
- name: Developmental Impairment
  description: Developmental impairment affecting speech, cognition, and behavior is common.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
- name: Hypotonia
  description: Muscular hypotonia occurs in some individuals.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
- name: Dystonia
  description: Dystonia occurs in some individuals.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
genetic:
- name: PNPO
  gene_term:
    preferred_term: PNPO
    term:
      id: hgnc:30260
      label: PNPO
  relationship_type: CAUSATIVE
  notes: >-
    PNPO (17q21.32) encodes pyridox(am)ine 5'-phosphate oxidase. Biallelic
    pathogenic variants (missense, splice, truncating) cause PNPO deficiency;
    genotype influences whether seizures respond to PLP or also to pyridoxine.
biochemical:
- name: Elevated Urinary Vanillactic Acid
  biomarker_term:
    preferred_term: vanillactic acid
  presence: INCREASED
  notes: >-
    Increased urinary vanillactic acid (from accumulation of the AADC substrate
    that is diverted when PLP-dependent decarboxylation fails) is the most
    sensitive biochemical clue.
  evidence:
  - reference: PMID:32888189
    reference_title: "Phenotypic and molecular spectrum of pyridoxamine-5'-phosphate oxidase deficiency: A scoping review of 87 cases of pyridoxamine-5'-phosphate oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebrospinal fluid (CSF) PLP was low in 81%, CSF glycine was high in 80% and urinary vanillactic acid was high in 91% of the cases."
    explanation: >-
      The scoping review quantifies the diagnostic biomarkers: urinary
      vanillactic acid high in 91%, CSF glycine high in 80%, CSF PLP low in 81%.
- name: Low CSF Pyridoxal 5-Phosphate
  biomarker_term:
    preferred_term: pyridoxal 5'-phosphate
    term:
      id: CHEBI:18405
      label: pyridoxal 5'-phosphate
  presence: DECREASED
  notes: >-
    CSF PLP is low in most (but not all) patients; a normal CSF PLP does not
    exclude the diagnosis.
  evidence:
  - reference: PMID:32888189
    reference_title: "Phenotypic and molecular spectrum of pyridoxamine-5'-phosphate oxidase deficiency: A scoping review of 87 cases of pyridoxamine-5'-phosphate oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebrospinal fluid (CSF) PLP was low in 81%, CSF glycine was high in 80% and urinary vanillactic acid was high in 91% of the cases."
    explanation: CSF PLP was low in 81% of cases.
- name: Elevated CSF Glycine
  biomarker_term:
    preferred_term: glycine
  presence: INCREASED
  notes: >-
    CSF glycine is elevated in most patients, reflecting impaired PLP-dependent
    glycine cleavage.
  evidence:
  - reference: PMID:32888189
    reference_title: "Phenotypic and molecular spectrum of pyridoxamine-5'-phosphate oxidase deficiency: A scoping review of 87 cases of pyridoxamine-5'-phosphate oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebrospinal fluid (CSF) PLP was low in 81%, CSF glycine was high in 80% and urinary vanillactic acid was high in 91% of the cases."
    explanation: CSF glycine was high in 80% of cases.
diagnosis:
- name: PNPO Molecular Genetic Testing and B6 Trial
  description: >-
    Diagnosis is established by a positive standardized vitamin B6 trial in an
    infant with treatment-resistant seizures together with biallelic pathogenic
    PNPO variants (or deficient PNPO enzyme activity).
  evidence:
  - reference: PMID:35737815
    reference_title: "PNPO Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of PNPO deficiency is established in a proband with suggestive findings"
    explanation: GeneReviews establishes the combined B6-trial-plus-molecular diagnostic pathway.
treatments:
- name: Pyridoxal 5-Phosphate Supplementation
  description: >-
    Lifelong pyridoxal 5'-phosphate (PLP, the active vitamin B6 cofactor) is the
    targeted therapy that controls seizures in most individuals; the lowest
    effective dose is used because of possible liver toxicity.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pyridoxal 5'-phosphate
      term:
        id: CHEBI:18405
        label: pyridoxal 5'-phosphate
  evidence:
  - reference: PMID:35737815
    reference_title: "PNPO Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Independent of age of onset, seizures respond to life-long treatment with a B6 vitamer: pyridoxal 5'-phosphate (PLP) in about 60% of affected individuals and pyridoxine (PN) in about 40%."
    explanation: >-
      GeneReviews documents PLP as the targeted therapy effective in most
      individuals.
- name: Pyridoxine Supplementation
  description: >-
    A minority of individuals respond to pyridoxine (PN) rather than PLP;
    pyridoxine can cause reversible sensory (or motor) neuropathy at high doses.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pyridoxine
      term:
        id: CHEBI:16709
        label: pyridoxine
- name: Antiseizure Medications to Avoid
  description: >-
    PLP-lowering antiseizure medications (carbamazepine, valproate, phenytoin,
    phenobarbital) should be avoided because they can further reduce plasma PLP.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:35737815
    reference_title: "PNPO Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Avoid anti-seizure medications (such as carbamazepine, valproate, phenytoin, and phenobarbital) that can reduce plasma PLP concentration."
    explanation: >-
      GeneReviews lists PLP-lowering antiseizure medications among agents to
      avoid.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: RARE
  notes: >-
    A rare autosomal recessive inborn error of vitamin B6 metabolism; no precise
    population rate is established. A scoping review assembled 87 reported cases,
    indicating the disorder's rarity while noting likely underdiagnosis given the
    treatable, potentially fatal-if-missed presentation.
  evidence:
  - reference: PMID:32888189
    reference_title: "Phenotypic and molecular spectrum of pyridoxamine-5'-phosphate oxidase deficiency: A scoping review of 87 cases of pyridoxamine-5'-phosphate oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A scoping review of 87 cases of pyridoxamine-5'-phosphate oxidase deficiency"
    explanation: >-
      Provides a literature case count reflecting the rarity of the disorder; no
      normalized population rate is asserted.
datasets: []
discussions:
- discussion_id: gap_pnpo_plp_vs_pyridoxine_responsiveness_and_diagnostic_caveat
  prompt: >-
    What determines whether an individual with PNPO deficiency responds to
    pyridoxal 5'-phosphate versus pyridoxine, does genotype predict it, and how
    should the diagnostic caveat that CSF PLP can be normal be handled to avoid
    missed diagnoses?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#B6-Vitamer-Responsive Neonatal Seizures
  - pathophysiology#Pyridoxal 5-Phosphate Deficiency
  rationale: >-
    Most individuals respond to PLP and a minority to pyridoxine, but the
    determinants (specific variant, residual enzyme activity) are incompletely
    defined, and choosing the wrong vitamer or dose has real consequences (PLP
    carries a risk of liver toxicity, high-dose pyridoxine of neuropathy).
    Compounding this, CSF PLP - an expected biomarker - can be normal in a
    genetically confirmed patient, so a normal level does not exclude the
    diagnosis. Resolving the genotype-to-vitamer map and the reliable diagnostic
    pathway is directly actionable for this treatable disorder.
  evidence:
  - reference: PMID:25762494
    reference_title: "Normal Cerebrospinal Fluid Pyridoxal 5'-Phosphate Level in a PNPO-Deficient Patient with Neonatal-Onset Epileptic Encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a normal CSF level of pyridoxal 5'-phosphate does not rule out PNPO deficiency."
    explanation: >-
      Documents that a normal CSF PLP does not exclude PNPO deficiency, the
      diagnostic caveat this gap concerns.
  proposed_experiments:
  - experiment_id: exp_pnpo_genotype_vitamer_response
    name: Genotype-to-vitamer-response mapping in PNPO deficiency
    description: >-
      Correlate PNPO variant class and residual enzyme activity (in vitro and in
      patient cells) with clinical response to PLP versus pyridoxine, to test
      whether functional genotype predicts the effective vitamer.
    experiment_type:
      preferred_term: genotype-response correlation experiment
    readouts:
    - name: Vitamer response by genotype
      target: pathophysiology#B6-Vitamer-Responsive Neonatal Seizures
      assays:
      - preferred_term: enzyme activity assay
      direction: POSITIVE
    controls:
    - name: Wild-type PNPO
      description: Wild-type enzyme as the activity reference.
    decision_criterion: >-
      Genotype predicts vitamer response if residual-activity class reliably
      separates PLP-responsive from pyridoxine-responsive individuals.
    would_support:
    - pathophysiology#B6-Vitamer-Responsive Neonatal Seizures

- discussion_id: gap_pnpo_prematurity_risk_versus_manifestation
  prompt: >-
    Are the prematurity and fetal distress so commonly seen at presentation of
    PNPO deficiency true predisposing factors, or early manifestations of the
    disease itself (for example in-utero seizures and distress)?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#B6-Vitamer-Responsive Neonatal Seizures
  rationale: >-
    Premature birth and fetal distress recur as associated features across PNPO
    cohorts. If they are prodromal manifestations of prenatal disease, they
    could serve as early warning signs prompting a B6 trial; if they are genuine
    modifiers, they might worsen outcome independently. Distinguishing the two
    affects both early recognition and prognostic counseling.
  evidence:
  - reference: PMID:32888189
    reference_title: "Phenotypic and molecular spectrum of pyridoxamine-5'-phosphate oxidase deficiency: A scoping review of 87 cases of pyridoxamine-5'-phosphate oxidase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pre-maturity and fetal distress, combined with neonatal seizures, are other associated key characteristics."
    explanation: >-
      Documents the recurrent prematurity/fetal-distress association whose causal
      status is the open question.
  proposed_experiments:
  - experiment_id: exp_pnpo_perinatal_association
    name: Perinatal-feature causal analysis in PNPO deficiency
    description: >-
      In a prospective PNPO cohort, relate prenatal/perinatal findings and
      timing of metabolite/PLP disturbance to gestational age and outcome, to
      test whether prematurity precedes or follows the earliest disease markers.
    experiment_type:
      preferred_term: perinatal association analysis experiment
    readouts:
    - name: Timing of perinatal features versus disease markers
      target: pathophysiology#B6-Vitamer-Responsive Neonatal Seizures
      assays:
      - preferred_term: clinical assessment
      direction: POSITIVE
    controls:
    - name: Gestational-age-matched comparison
      description: Comparison against gestational-age-matched populations.
    decision_criterion: >-
      Prematurity is an early manifestation if it co-occurs with or follows the
      earliest disease markers rather than independently preceding them.
    would_support:
    - pathophysiology#B6-Vitamer-Responsive Neonatal Seizures

- discussion_id: gap_pnpo_shared_plp_pathway_with_pde_and_residual_impairment
  prompt: >-
    PNPO deficiency and ALDH7A1 pyridoxine-dependent epilepsy both converge on
    intracellular pyridoxal 5'-phosphate deficiency yet differ in vitamer
    responsiveness and treatment safety - why does developmental impairment
    persist despite vitamer treatment, and does the shared final pathway imply
    shared adjunct strategies?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Neurodevelopmental Impairment
  - pathophysiology#Pyridoxal 5-Phosphate Deficiency
  rationale: >-
    Both PNPO deficiency and ALDH7A1 pyridoxine-dependent epilepsy produce a
    functional PLP deficiency and a treatable neonatal epilepsy, but PNPO usually
    needs PLP (with hepatotoxicity risk) while ALDH7A1 needs pyridoxine (plus
    metabolite-lowering diet). In both, seizures respond yet a substantial share
    of patients have lasting developmental impairment. Whether the residual
    impairment reflects the shared PLP-cofactor failure (broad neurotransmitter
    and metabolic disruption) during a critical window, and whether adjuncts
    proven in one disorder transfer to the other, is an open, clinically relevant
    question. This entry deliberately mirrors the Pyridoxine-Dependent Epilepsy
    entry's dissociation gap.
  evidence:
  - reference: PMID:15772097
    reference_title: "Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "reduced activity of aromatic L-amino acid decarboxylase and other PLP-dependent enzymes."
    explanation: >-
      Establishes the broad PLP-cofactor failure shared with other PLP-deficiency
      epilepsies, the basis for asking about residual impairment and shared
      adjuncts.
  proposed_experiments:
  - experiment_id: exp_pnpo_pde_shared_pathway
    name: Shared PLP-deficiency mechanisms across PNPO and ALDH7A1 disease
    description: >-
      Compare neuronal PLP-dependent enzyme activity, neurotransmitter profiles,
      and developmental readouts across PNPO-deficient and ALDH7A1-deficient
      human neuronal models under vitamer treatment, to identify shared residual
      deficits and transferable adjunct targets.
    experiment_type:
      preferred_term: cross-disorder shared-pathway experiment
    readouts:
    - name: Residual PLP-dependent deficits under treatment
      target: pathophysiology#Neurodevelopmental Impairment
      assays:
      - preferred_term: enzyme activity assay
      - preferred_term: metabolite profiling assay
      direction: POSITIVE
    controls:
    - name: Vitamer-treated wild-type
      description: Wild-type neurons under matched vitamer treatment.
    decision_criterion: >-
      A shared residual mechanism is supported if both disorders retain the same
      PLP-dependent deficits under vitamer treatment, nominating a common adjunct
      target.
    would_support:
    - pathophysiology#Neurodevelopmental Impairment
references:
- reference: PMID:35737815
  title: "PNPO Deficiency."
  tags:
  - GeneReviews
  findings: []

📚

References & Deep Research

References

1

PMID:35737815

PNPO Deficiency.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

1. Disease Information

claude-haiku-4-5-20251001, claude-opus-4-8 12 citations 2026-07-18T09:04:21.232884

1. Disease Information

PNPO deficiency (pyridox(am)ine 5′-phosphate oxidase deficiency) is an autosomal recessive inborn error of vitamin B6 metabolism. Loss of PNPO enzyme activity starves the brain of pyridoxal 5′-phosphate (PLP) — the biologically active form of vitamin B6 and an obligate cofactor for ~140 human enzymes, including several that make and break neurotransmitters. The result is a neonatal-onset developmental and epileptic encephalopathy that resists ordinary anticonvulsants but responds, sometimes dramatically, to B6 vitamers.

Key identifiers: - MONDO: MONDO:0012407 - OMIM: #610090 (PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD) - Orphanet: ORPHA:79096 ("Pyridoxamine-5-phosphate deficiency–developmental and epileptic encephalopathy") - Gene OMIM: 603287 (PNPO) - HGNC: HGNC:30260

Synonyms / alternative names: Pyridoxal 5′-phosphate-responsive (or -dependent) seizures; pyridoxine-5′-phosphate oxidase deficiency; neonatal epileptic encephalopathy, PNPO-related; "seizures, pyridoxine-resistant, PLP-sensitive." Note the naming quirk worth flagging for curation: the enzyme is pyridox(am)ine 5′-phosphate oxidase (it acts on both pyridoxine phosphate and pyridoxamine phosphate), but OMIM titles the disease "pyridoxamine 5-prime-phosphate oxidase deficiency."

Data provenance: Disease-level aggregated resources (OMIM, Orphanet, GeneReviews, plus a 2021 scoping review of 87 published cases and a 2022/2023 cohort). There is no large EHR-derived cohort — this is a very rare Mendelian disorder documented case-by-case in the literature.

Sources: OMIM 610090, Orphanet, GeneReviews NBK581452, MedlinePlus.

2. Etiology

Primary cause — genetic: Biallelic (homozygous or compound heterozygous) pathogenic variants in PNPO (17q21.32) causing loss or reduction of pyridox(am)ine 5′-phosphate oxidase activity, and thus systemic/CNS PLP deficiency. There is no environmental or infectious cause of the disease itself.

Risk factors: - Genetic: being a carrier of two pathogenic PNPO alleles is necessary and (mostly) sufficient. Consanguinity raises risk of homozygosity and is over-represented in case series. No modifier genes are firmly established. - Environmental / perinatal: Prematurity and fetal distress are strikingly common at presentation. In the original Mills 2005 series and the 87-case scoping review, premature birth and fetal distress recur as associated features — though it's debated whether these are true risk factors or early manifestations of the disease (in-utero seizures/distress). Because PLP is also required for many metabolic pathways, states of increased B6 demand can unmask or worsen symptoms.

Protective factors: There are no known genetic protective alleles. The one dominant "protective" lever is exogenous B6 vitamer supplementation (PLP or pyridoxine) — pharmacologic, not dietary-preventive in the ordinary sense. Reduced penetrance in some genotypes (see §9) hints at unidentified modifiers/environmental buffers, but these are uncharacterized.

Gene–environment interaction: The clearest interaction is genotype × B6 supply. A hypomorphic (partial-activity) genotype such as p.Arg116Gln can remain subclinical until a period of physiologic B6 stress, which is why some homozygotes never seize. This is the "leaky enzyme meets a demanding day" pattern.

Sources: Mills 2005, PMID 15772097; Alghamdi 2021 scoping review, PMID 32888189; GeneReviews.

3. Phenotypes

The core phenotype is a severe seizure disorder of neonatal onset, but the spectrum is broad. Onset distribution (Alghamdi 2021; GeneReviews): - "Classic" neonatal onset: ~89–90% — seizures often on day one of life, typically before age two weeks. - "Late onset": ~10% — after the neonatal period, occasionally out to ~5 months (median onset in one cohort was 6.5 days; 67% before one month, 39% within 24 hours of birth — HMG 2022/2023, Ciapaite et al.).

Seizure/neurological phenotypes (signs & symptoms): | Phenotype | Notes / frequency | Suggested HPO | |---|---|---| | Seizures, drug-resistant | Near-universal; the defining feature | HP:0001250 Seizure | | Neonatal onset seizures | ~90% | HP:0032807 Neonatal seizure | | Developmental and epileptic encephalopathy | Core diagnosis | HP:0200134 Developmental and epileptic encephalopathy | | Status epilepticus | Frequent in classic presentation | HP:0002133 Status epilepticus | | Myoclonic seizures | Common; also clonic and tonic | HP:0032794 Myoclonic seizure | | Clonic / tonic seizures | Multiple seizure types coexist | HP:0020221 Clonic seizure; HP:0032792 Tonic seizure | | Burst-suppression EEG | 17/41 in GeneReviews EEG review | HP:0010851 EEG with burst suppression | | Hypsarrhythmia | 3/41 | HP:0002521 Hypsarrhythmia | | Abnormal fetal movements / in-utero seizures | Reported | HP:0001557 Abnormal fetal physiology (approx.) | | Encephalopathy | Following seizure onset | HP:0001298 Encephalopathy | | Hypotonia / abnormal tone | Common | HP:0001252 Hypotonia | | Irritability, poor feeding | Neonatal nonspecific signs | HP:0000737 Irritability |

Systemic / associated phenotypes: - Prematurity (~very frequent) — HP:0001622 Premature birth - Fetal distress — HP:0001560 Abnormal umbilical cord blood vessel morphology (approx.; use clinical descriptor) - Small for gestational age / low birth weight reported — HP:0001518

Neurodevelopmental outcome phenotypes (later): - Intellectual disability / global developmental delay: ~56–60% even with seizure control — HP:0001249 Intellectual disability; HP:0001263 Global developmental delay - Speech impairment, autism-like behavior (reported with R116Q/E50K) — HP:0000750 Delayed speech; HP:0000729 Autistic behavior - Microcephaly in some — HP:0000252

Laboratory-abnormality phenotypes (see §10 for detail): low CSF PLP, elevated CSF glycine and threonine, elevated urinary vanillactic acid, elevated CSF/plasma 3-methoxytyrosine, low homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA).

Severity/progression: Untreated classic disease is severe and can be fatal. Course is episodic seizures on a background of encephalopathy; once the correct vitamer is started, seizures typically stop within 1–3 days, but neurodevelopmental sequelae may persist.

Quality-of-life impact: For untreated or late-treated patients, profound — refractory seizures, intellectual disability, dependency. Early-treated patients can have markedly better trajectories, but lifelong supplementation and monitoring are required, and a subset carries residual cognitive/behavioral disability. No formal EQ-5D/SF-36 data exist for this ultra-rare disease.

Sources: Alghamdi 2021, PMID 32888189; GeneReviews; HMG 2023.

4. Genetic / Molecular Information

Causal gene: PNPO (pyridoxamine 5′-phosphate oxidase), 17q21.32, HGNC:30260, gene OMIM 603287. Encodes a ~261-amino-acid FMN-dependent oxidase.

Pathogenic variants: More than 30 pathogenic variants are genetically confirmed — missense, nonsense/stop, splice-site, and small indels. Landmark and illustrative examples: - c.674G>A, p.Arg225His (R225H): conserved PLP/substrate-binding region; enzyme kinetics ~27-fold lower k_cat and 6-fold higher K_m vs wild type (Sci Rep 2020, PMC7424515). - c.685C>T, p.Arg229Trp (R229W): original Mills 2005 missense; markedly reduced activity (PMID 15772097). - IVS3-1G>A (c.364-1G>A): canonical splice-acceptor variant, abolishes function; a recurrent allele. - X262Q (stop-loss/read-through): catalytically inactive and "almost devoid of FMN." - p.Gly118Arg (G118R): ~7-fold weaker FMN binding. - p.Arg141Cys (R141C): k_cat >3× lower than wild type. - c.347G>A, p.Arg116Gln (R116Q): hypomorphic / partial-activity variant associated with later onset, milder or even non-penetrant disease — though a compound-heterozygous R116Q/E50K patient had severe ID and autism-like features, showing it isn't uniformly mild (HMG 2023; PMID 28818555).

Variant classification: Per ACMG/AMP in ClinVar/ClinGen, most recurrent alleles are Pathogenic/Likely Pathogenic; R116Q is notable as a lower-penetrance/hypomorphic allele. Allele frequency: individual pathogenic alleles are rare in gnomAD; R116Q is comparatively more frequent, consistent with its milder effect and carrier tolerance.

Somatic vs germline: Entirely germline. Functional consequence: loss of function (reduced/absent catalytic activity, impaired FMN binding, or protein instability) — no gain-of-function or dominant-negative mechanism.

Modifier genes / epigenetics / chromosomal abnormalities: No established modifier genes, no epigenetic mechanism, no large chromosomal rearrangements implicated. Reduced penetrance of R116Q suggests unidentified modifiers.

Suggested annotations: gene → HGNC:30260 (PNPO); GO:0004733 (pyridoxamine phosphate oxidase activity), GO:0010181 (FMN binding).

Sources: Mills 2005; Sci Rep 2020; HMG 2023; PMID 28818555; ClinVar.

5. Environmental Information

PNPO deficiency is a monogenic disorder — no environmental agent causes it. Relevant modifiers of expression/severity: - B6 nutritional status / demand: physiologic states of high vitamin B6 requirement can unmask hypomorphic genotypes. - Perinatal factors: prematurity and fetal distress cluster with presentation (cause-vs-consequence unresolved). - Drug interactions: classic anticonvulsants are ineffective; there are anecdotal reports of paradoxical worsening, and some B6-antagonizing exposures could theoretically aggravate CNS PLP deficiency. - Infectious agents: none — not applicable.

Source: GeneReviews.

6. Mechanism / Pathophysiology

The causal chain (upstream → downstream):

Enzyme lesion. PNPO is the terminal enzyme of the vitamin B6 salvage pathway. It's an FMN-dependent homodimeric oxidase that transfers a hydride from the C4′ of pyridoxine 5′-phosphate (PNP) or pyridoxamine 5′-phosphate (PMP) to tightly bound FMN, generating pyridoxal 5′-phosphate (PLP) (Sci Rep 2020). Human PNPO also has a secondary allosteric PLP-binding site that mediates product feedback inhibition and is thought to channel newly made PLP directly to apo-enzymes.
PLP deficiency. Loss of PNPO activity means PNP/PMP can't be oxidized to PLP. Because pyridoxine (dietary B6) enters mainly through the PNP→PLP route, patients are pyridoxine-resistant — giving PN doesn't help if PNPO is dead — but can be rescued by exogenous PLP (bypassing the block) and, in some genotypes, still by high-dose PN if residual activity exists. Dietary pyridoxamine can also feed in via PMP in models.
Failure of PLP-dependent neurotransmitter metabolism. PLP is the cofactor for the enzymes that make and regulate key neurotransmitters. The deficiency hits:
Glutamate decarboxylase (GAD) → ↓GABA (loss of principal inhibition → hyperexcitability/seizures)
Aromatic L-amino acid decarboxylase (AADC) → ↓dopamine, ↓serotonin; substrate L-dopa backs up and is O-methylated to 3-methoxytyrosine; downstream metabolites HVA and 5-HIAA fall
Glycine cleavage system / threonine dehydratase → ↑glycine, ↑threonine
Excess L-dopa/L-amino acids shunt to vanillactic acid (elevated in urine — a biochemical fingerprint)

Mills 2005 showed exactly this: "reduced activity of aromatic L-amino acid decarboxylase and other PLP-dependent enzymes," i.e., a global PLP-cofactor failure (PMID 15772097).

Net excitation/inhibition imbalance → seizures & encephalopathy. The GABA deficit plus monoamine deficiency produces the excitation–inhibition imbalance underlying the epileptic encephalopathy — this is the disorder's natural conformance target to the epilepsy_excitation_inhibition_imbalance module (#Excitation-Inhibition Imbalance).

Molecular pathways: Vitamin B6 (pyridoxal) salvage/metabolic pathway; PLP biosynthesis (GO:0042823 pyridoxal phosphate biosynthetic process); GABA biosynthesis (GO:0009449); catecholamine/serotonin biosynthesis. Reactome/KEGG: "Vitamin B6 metabolism."

Cellular processes: Neuronal excitability regulation; neurotransmitter biosynthesis; oxidative/energetic stress secondary to seizures. Because PLP touches ~140 enzymes (amino-acid, one-carbon, heme, sphingolipid metabolism), there is broad but neuro-dominant metabolic disruption.

Protein dysfunction: Loss of catalytic efficiency (↓k_cat, ↑K_m), impaired FMN binding (e.g., G118R, X262Q "almost devoid of FMN"), and/or destabilization. Notably, most characterized mutants retain allosteric PLP inhibition — the defect is selectively catalytic, not regulatory (Sci Rep 2020).

Metabolic changes: ↓PLP (CSF/plasma), ↓GABA, ↓dopamine/serotonin (↓HVA/↓5-HIAA), ↑3-methoxytyrosine, ↑L-dopa, ↑glycine, ↑threonine, ↑urinary vanillactic acid.

Immune involvement: None. Tissue damage: Secondary hypoxic-ischemic and excitotoxic injury from status epilepticus; a distinct concern is iatrogenic hepatotoxicity from high-dose PLP (see §11–12).

Suggested annotations: GO:0042823 (PLP biosynthetic process), GO:0004733 (pyridoxamine phosphate oxidase activity), GO:0010181 (FMN binding), GO:0009449 (GABA biosynthetic process); CHEBI:18405 (pyridoxal 5′-phosphate), CHEBI:28803 (pyridoxine 5′-phosphate), CHEBI:18335 (pyridoxamine 5′-phosphate), CHEBI:16709 (pyridoxine), CHEBI:17621 (FMN), CHEBI:16865 (GABA); cell type CL:0000540 (neuron).

Sources: Mills 2005; Sci Rep 2020; GeneReviews.

7. Anatomical Structures Affected

Organ level: Central nervous system / brain is the primary target (UBERON:0000955 brain; UBERON:0001017 CNS). Secondary hepatic involvement is treatment-related (high-dose PLP → transaminitis, cirrhosis, rare hepatocellular carcinoma; UBERON:0002107 liver).
Body systems: Nervous system (primary); hepatobiliary (iatrogenic); the disorder is fundamentally a systemic metabolic defect with CNS-dominant expression.
Tissue/cell level: Neurons across cerebral cortex and deep gray matter; GABAergic and monoaminergic (dopaminergic/serotonergic) neuronal populations are functionally most affected because their transmitter synthesis is PLP-dependent (CL:0000617 GABAergic neuron; CL:0000700 dopaminergic neuron; CL:0000850 serotonergic neuron).
Subcellular level: Cytosol (site of PNPO activity and neurotransmitter-synthesizing decarboxylases; GO:0005829 cytosol). PLP synthesis and channeling to apo-enzymes occur cytosolically.
Localization / lateralization: Diffuse, bilateral CNS involvement; EEG shows multifocal/bilateral discharges and burst suppression. MRI is often normal early but can show cerebral edema, white-matter signal change, delayed myelination, intraventricular hemorrhage, atrophy, or ischemic change (GeneReviews: of 55 later cases, 34 normal, 8 atrophy, 3 ischemic).

Sources: GeneReviews; Alghamdi 2021.

8. Temporal Development

Onset: Congenital/neonatal in ~90% — frequently within hours of birth, before two weeks; ~39% within the first 24 hours. Late-onset (~10%) extends into infancy (up to ~5 months). Onset pattern is acute (abrupt refractory seizures), sometimes preceded by reported abnormal fetal movements/in-utero seizures.
Progression: Untreated → severe, potentially fatal epileptic encephalopathy. With the correct vitamer, seizures usually cease within 1–3 days and EEG improves. Course is then chronic and lifelong-supplement-dependent; breakthrough seizures occur if therapy is interrupted or under-dosed, or during intercurrent illness.
Stages: (1) acute neonatal refractory seizures/status; (2) treatment-responsive stabilization; (3) chronic maintenance with variable residual neurodevelopmental disability.
Remission: Treatment-induced seizure control, not spontaneous. Rare hypomorphic genotypes may be effectively subclinical (non-penetrant).
Critical period: The therapeutic window is early — shorter diagnostic delay (roughly <4 weeks to effective treatment) correlates with better neurodevelopmental outcomes. This is the single most actionable variable.

Sources: GeneReviews; Alghamdi 2021; HMG 2023.

9. Inheritance and Population

Epidemiology: Ultra-rare. Orphanet lists prevalence as unknown/<1 in 1,000,000; GeneReviews notes ~90 individuals worldwide with biallelic pathogenic PNPO variants reported as of 2022. True incidence/prevalence is undefined; likely under-ascertained because untreated neonates may die before diagnosis.
Inheritance: Autosomal recessive (HP:0000007). Requires biallelic pathogenic variants.
Penetrance: Generally high for null/severe genotypes; reduced/incomplete for the hypomorphic p.Arg116Gln — "not all individuals homozygous for the variant p.Arg116Gln develop seizures."
Expressivity: Variable, even among individuals sharing a genotype; molecular severity correlates only weakly with neurodevelopmental outcome.
Genetic anticipation: Not applicable (not a repeat-expansion disorder).
Germline mosaicism: Not specifically reported.
Founder effects / consanguinity: Consanguinity is over-represented; several recurrent alleles (e.g., IVS3-1G>A, R116Q) suggest founder contributions in specific populations. R116Q is comparatively more common in population databases.
Carrier frequency: Not precisely established; individual pathogenic alleles are rare in gnomAD.
Demographics: Reported worldwide across many ethnicities; no strong sex bias (autosomal). Age distribution is heavily neonatal/infantile.

Sources: Orphanet; GeneReviews; OMIM 610090.

10. Diagnostics

The diagnostic reality: there is no single reliable biochemical biomarker — molecular confirmation is required. "There is no diagnostic biomarker, and molecular testing required for diagnosis" (Alghamdi 2021).

Biochemical / laboratory tests (supportive, not definitive): - CSF PLP: low in ~81% of cases (but can be normal — a normal CSF PLP does not exclude the diagnosis; PMID 25762494) — LOINC-codable analyte - Urinary vanillactic acid: elevated in ~91% — the most sensitive single metabolic clue - CSF glycine elevated ~80%; CSF threonine elevated - CSF 3-methoxytyrosine (3-OMD) elevated, with low HVA and 5-HIAA (AADC dysfunction signature) - Plasma pyridoxic acid and B6 vitamer profiling can help - These profiles overlap with AADC deficiency, PLPBP/PROSC deficiency, and pyridoxine-dependent epilepsy (ALDH7A1) — hence molecular testing is decisive.

Neurophysiology: EEG frequently shows burst suppression (17/41), multifocal/bilateral discharges (17/41), hypsarrhythmia (3/41), rarely normal (4/41).

Imaging: MRI often normal early; may later show edema, delayed myelination, white-matter change, hemorrhage, atrophy, or ischemia. Imaging supports rather than confirms.

Genetic testing (definitive): - Recommended approach: molecular confirmation of biallelic PNPO variants — via a gene panel (epileptic encephalopathy / vitamin-B6-responsive seizure panel), WES, or WGS; targeted single-gene sequencing where clinical suspicion is high. Enzyme activity assays exist but are research-grade. - CMA/karyotype/FISH/mtDNA/repeat-expansion testing are not indicated (point-mutation, autosomal, non-repeat disease).

Clinical criteria / differential diagnosis: No formal consensus criteria. Diagnosis = suggestive clinical picture (neonatal refractory seizures unresponsive to standard antiseizure meds) + B6 vitamer trial response + biallelic PNPO variants (or deficient enzyme activity). Differential: pyridoxine-dependent epilepsy (ALDH7A1), PLPBP/PROSC deficiency, AADC deficiency, other early-infantile DEEs, hypoxic-ischemic encephalopathy.

Screening: No routine newborn screening exists (vanillactic acid is not a standard NBS analyte). Cascade/carrier testing for at-risk families and prenatal/preimplantation testing are available once familial variants are known.

Suggested annotations: MAXO — clinical/genetic testing; LOINC — CSF PLP, urinary vanillactic acid.

Sources: Alghamdi 2021; GeneReviews; PMID 25762494.

11. Outcome / Prognosis

Survival/mortality: Untreated classic PNPO deficiency can be fatal in the neonatal period. With prompt correct treatment, survival is substantially improved, though deaths still occur, especially with delayed diagnosis. No formal survival curves exist for this ultra-rare disease.
Seizure outcome: ~60% become seizure-free on PLP, ~40% respond to pyridoxine; overall the majority achieve seizure control with the correct vitamer, usually within 1–3 days.
Neurodevelopmental morbidity: ~56–60% have developmental delay/intellectual disability despite seizure control — the sobering gap between "seizures stopped" and "brain protected." Speech, cognition, and behavior are commonly affected.
Prognostic factors: Better outcomes correlate with shorter treatment delay (<4 weeks), later/less severe onset, and absence of prematurity. Worse outcomes: prematurity, early seizure onset, delayed PLP initiation. Genotype severity is only a weak predictor of neurocognitive outcome.
Iatrogenic risk: High-dose PLP hepatotoxicity — mild transaminitis at ~50 mg/kg/day; cirrhosis reported at ages 4 and 8 on 50–100 mg/kg/day; one adolescent required liver transplant at 15 for hepatocellular carcinoma. This makes hepatic monitoring and dose minimization part of prognosis.

Sources: Alghamdi 2021; GeneReviews.

12. Treatment

The whole game is replacing the missing active cofactor and doing it fast.

Pharmacotherapy (vitamer replacement): - Pyridoxal 5′-phosphate (PLP) — first-line for PNPO deficiency; bypasses the enzyme block. Dose ~30–60 mg/kg/day orally, divided into 4–6 doses. ~60% of patients are PLP-responsive. (CHEBI:18405; MAXO:0000088 dietary supplementation / MAXO pharmacotherapy; NCIT:C15986 Pharmacotherapy with therapeutic_agent = pyridoxal phosphate.) - Pyridoxine (PN) — ~40% respond, especially hypomorphic genotypes with residual activity. Dose ~30 mg/kg/day (up to ~300–500 mg/day) divided 3–4×. (CHEBI:16709.) - Pyridoxamine — in the zebrafish model, rescued the phenotype at lower concentration than PLP and is proposed as a possible future therapy; not yet standard human care. (CHEBI:44309.) - Note on safety: because of PLP hepatotoxicity, some clinicians favor the lowest effective dose and monitor liver function; a trial of PN is reasonable in responders to avoid PLP's hepatic risk.

Adjuncts: Standard antiseizure medications are ineffective as monotherapy but may be used situationally. Supportive neonatal intensive care for status epilepticus.

Pharmacogenomics / personalized medicine: Treatment choice is effectively genotype-guided — null alleles → PLP-dependent; hypomorphic alleles (e.g., R116Q) may respond to PN. This is a clean example of genotype-directed vitamer selection.

Advanced/experimental therapeutics: No approved gene, cell, or RNA therapy. Pyridoxamine and optimized dosing are the active research fronts; no PNPO-specific NCT trials of gene therapy are established. Lifelong supplementation is the standard.

Treatment strategy / algorithm: In any neonate with unexplained refractory seizures → empiric B6 vitamer trial (pyridoxine, then PLP) under monitoring, alongside urgent molecular testing; if PNPO-confirmed, establish lifelong PLP (or PN) maintenance at the lowest effective dose with hepatic surveillance.

Suggested annotations: MAXO:0000088 (dietary intervention/supplementation); NCIT:C15986 (Pharmacotherapy) + therapeutic_agent CHEBI:18405 (PLP), CHEBI:16709 (pyridoxine).

Sources: GeneReviews; Alghamdi 2021; zebrafish, PMC6764245.

13. Prevention

Primary prevention: Not preventable in a carrier couple's affected pregnancy beyond reproductive planning. Genetic counseling for AR recurrence risk (25% per pregnancy for carrier couples), carrier/cascade testing, and prenatal or preimplantation genetic testing once familial variants are known. (MAXO:0000079 genetic counseling.)
Secondary prevention (early detection): The highest-yield lever. Early recognition and empiric B6 vitamer trial in neonates with refractory seizures prevents seizure-related brain injury. No population newborn screening exists; presymptomatic treatment of a genotype-positive sibling is reasonable given the tight therapeutic window.
Tertiary prevention: In diagnosed patients — uninterrupted maintenance supplementation, dose optimization to avoid breakthrough seizures, increased vitamer during intercurrent illness/metabolic stress, and hepatic monitoring to prevent PLP toxicity.
Immunization / public health / environmental interventions: Not applicable (monogenic, non-infectious).

Sources: GeneReviews.

14. Other Species / Natural Disease

Taxonomy: Human disease (NCBITaxon:9606). PNPO orthologs are broadly conserved across vertebrates and beyond (yeast PNP oxidase, E. coli PdxH).
Orthologous genes: mouse Pnpo (chr 11), zebrafish pnpo; conserved FMN-oxidase family.
Natural disease in animals: No well-documented spontaneous naturally-occurring PNPO-deficiency disease in companion animals or livestock is established in OMIA to the level of human characterization; the animal data are engineered models (below).
Comparative biology: The enzymatic reaction and PLP-dependent neurotransmitter dependence are deeply evolutionarily conserved, which is why cross-species models recapitulate core features. Zoonotic potential/cross-species transmission: not applicable.

Sources: zebrafish study, PMC6764245; Sci Rep 2020.

15. Model Organisms

Zebrafish (Danio rerio) pnpo morphant/knockdown — the flagship model. Shows brain malformation, impaired locomotor activity, incomplete neural tube closure, small eyes, body curvature, heart defects, malformed swim bladder, and dose-dependent lethality. Behaviorally, increased spontaneous erratic movements at 1 dpf progressing to reduced activity by 4 dpf ("neuron damage" rather than classic epilepsy). GABA supplementation partially rescued (implicating low GABA), and — key translational finding — pyridoxamine rescued at lower concentration than PLP, plus PLP rescued morphology and improved survival (PMC6764245). Evidence source: MODEL_ORGANISM.
Mouse Pnpo variant models — a mouse carrying the human-equivalent c.347G>A (p.Arg116Gln) hypomorphic allele reproduces biochemical alterations, useful for studying the partial-activity/late-onset end of the spectrum (PMID 28818555). Evidence source: MODEL_ORGANISM.
In-vitro recombinant enzyme systems — purified wild-type and mutant human PNPO (R225H, G118R, X262Q, R141C, etc.) characterized for kinetics, FMN binding, and allosteric PLP inhibition, defining loss-of-function mechanisms at the protein level (Sci Rep 2020, PMC7424515). Evidence source: IN_VITRO.

Model utility & limitations: Zebrafish capture developmental/neurobehavioral consequences and enable rapid vitamer-rescue screening but do not reproduce human neonatal burst-suppression seizures faithfully; recombinant enzymes explain genotype→activity but not organismal outcome; the R116Q mouse models the mild/hypomorphic end. Together they support the mechanistic chain (enzyme loss → PLP deficiency → GABA/monoamine failure → neuro dysfunction, vitamer-rescuable). This is a good candidate for a HUMAN_MODEL_MISMATCH discussion note in the entry, since zebrafish behavior ≠ human epileptic encephalopathy.

Resources: ZFIN (zebrafish), MGI (mouse).

Curation Notes (dismech-specific)

Module conformance: natural fit for epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance (GABA deficit → hyperexcitability). Also arguably metabolic_intoxication_decompensation-adjacent conceptually, but PNPO is a cofactor-deficiency/neurotransmitter-synthesis defect rather than a toxic-metabolite intoxication — I'd keep it on the epilepsy module and treat the metabolic angle as disease-specific pathophysiology rather than forcing the intoxication module.
NEC caution: the "pyridoxamine vs pyridox(am)ine vs pyridoxine 5′-phosphate oxidase" naming, plus overlap with ALDH7A1 pyridoxine-dependent epilepsy and PLPBP/PROSC deficiency, is a real named-entity-confusion trap. Anchor every evidence item on PNPO / MONDO:0012407 / OMIM 610090 and verify the gene named in each cited paper is PNPO, not ALDH7A1 or PLPBP, before committing snippets.
Evidence discipline reminder: every snippet above is paraphrased for this report — before it lands in YAML, each PMID needs just fetch-reference and an exact-substring snippet check. Treat the WebFetch paraphrases as leads, not quotes.

Primary citations to seed the entry: PMID 15772097 (Mills 2005, foundational), PMID 32888189 (Alghamdi 2021, 87-case scoping review), GeneReviews NBK581452, HMG 2023 (Oxford, variable manifestations), Sci Rep 2020 / PMC7424515 (enzyme characterization), PMC6764245 (zebrafish), PMID 28818555 (R116Q mouse), PMID 25762494 (normal CSF PLP caveat).

Sources: - OMIM #610090 - Orphanet ORPHA:79096 - GeneReviews: PNPO Deficiency (NBK581452) - Mills et al. 2005, PMID 15772097 - Alghamdi et al. 2021 scoping review, PMID 32888189 - Ciapaite et al., Human Molecular Genetics 2023 - Molecular characterization of PNPO, Sci Rep 2020 / PMC7424515 - Zebrafish pnpo model, PMC6764245 - R116Q Pnpo mouse, PMID 28818555 - Normal CSF PLP in PNPO deficiency, PMID 25762494 - MedlinePlus Genetics: pyridoxal phosphate-responsive seizures

PNPO Deficiency

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Prevalence

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Curation Notes (dismech-specific)